Wedge Capital Management’s Anika Therapeutics ANIK Stock Holding History

Wedge Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-22,600	Closed	-$921K	–	594
2014 Q4	$921K	Hold	22,600	–	–	0.01%	347
2014 Q3	$829K	Buy	22,600 +2,200	+11%	+$95.1K	0.01%	358
2014 Q2	$945K	Sell	20,400 -4,100	-17%	-$182K	0.01%	342
2014 Q1	$1.01M	Sell	24,500 -4,100	-14%	-$152K	0.01%	333
2013 Q4	$1.09M	Sell	28,600 -5,400	-16%	-$167K	0.01%	314
2013 Q3	$812K	Sell	34,000 -18,000	-35%	-$404K	0.01%	330
2013 Q2	$884K	Buy	+52,000	New	+$750K	0.01%	318

Other funds holding ANIK

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LCP

Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Wedge Capital Management's ANIK Position: Q1 2015 in Review

Wedge Capital Management sold out of Anika Therapeutics (ANIK) in Q1 2015, closing a stake of 22,600 shares — an estimated $921K sold.

Wedge Capital Management first reported a position in ANIK in Q2 2013 and held it in 7 quarters. The position peaked at $1.09M in Q4 2013. 159 funds tracked by Wall St. Rank hold ANIK as of Q1 2015.

Wedge Capital Management reported no remaining Anika Therapeutics position as of Q1 2015 after selling out during the quarter.
Wedge Capital Management sold 22,600 Anika Therapeutics shares in Q1 2015, an estimated $921K.
Wedge Capital Management first reported a position in Anika Therapeutics in Q2 2013 and held it in 7 quarters.
Wedge Capital Management's Anika Therapeutics position peaked at $1.09M in Q4 2013.
159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2015.

Based on Wedge Capital Management's 13F filing for Q1 2015, filed 1 May 2015.